> Detailanzeige

Scheipl, Susanne; Froehlich, Elke V; Leithner, Andreas; Beham, Alfred; Quehenberger, Franz; Mokry, Michael; Stammberger, Heinz; Varga, Peter P; Lazáry, Aron; Windhager, Reinhard; Gattenloehner, Stefan; Liegl, Bernadette

Does insulin‐like growth factor 1 receptor (IGF‐1R) targeting provide new treatment options for chordomas? A retrospective clinical and immunohistochemical study

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Does insulin‐like growth factor 1 receptor (IGF‐1R) targeting provide new treatment options for chordomas? A retrospective clinical and immunohistochemical study
  • Beteiligte: Scheipl, Susanne; Froehlich, Elke V; Leithner, Andreas; Beham, Alfred; Quehenberger, Franz; Mokry, Michael; Stammberger, Heinz; Varga, Peter P; Lazáry, Aron; Windhager, Reinhard; Gattenloehner, Stefan; Liegl, Bernadette
  • Erschienen: Wiley, 2012
  • Erschienen in: Histopathology
  • Sprache: Englisch
  • DOI: 10.1111/j.1365-2559.2012.04186.x
  • ISSN: 0309-0167; 1365-2559
  • Schlagwörter: General Medicine ; Histology ; Pathology and Forensic Medicine
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:p>Scheipl S, Froehlich E V, Leithner A, Beham A, Quehenberger F, Mokry M, Stammberger H, Varga P P, Lazáry A, Windhager R, Gattenloehner S &amp; Liegl B 
(2012) <jats:italic>Histopathology</jats:italic> <jats:bold>60,</jats:bold> 999–1003</jats:p><jats:p><jats:bold>Does insulin‐like growth factor 1 receptor (IGF‐1R) targeting provide new treatment options for chordomas? A retrospective clinical and immunohistochemical study</jats:bold></jats:p><jats:p><jats:bold>Aims: </jats:bold> The overall prognosis of chordoma is poor, and current treatment options are limited. The insulin‐like growth factor 1 receptor (IGF‐1R) pathway is important for cell signalling, and attractive for selective inhibition. We investigated the expression of IGF‐1R and its ligands, IGF‐1 and IGF‐2, in a series of 50 chordomas, in order to assess whether IGF‐1R‐signalling could be a potential target for specific inhibition in chordomas.</jats:p><jats:p><jats:bold>Methods and results: </jats:bold> Fifty chordomas (34 primary tumours, 16 recurrences) from 44 patients were evaluated immunohistochemically for the expression of IGF‐1R, IGF‐1 and IGF‐2. Thirty‐eight chordomas (76%) expressed IGF‐1R, 46 (92%) expressed IGF‐1 and 25 (50%) expressed IGF‐2. Semi‐quantitative analyses revealed a moderate to strong staining intensity in ≥50% of tumour cells for IGF‐1R, IGF‐1 and IGF‐2 in 18 (36%), 32 (64%) and eight (16%) chordomas, respectively. Tumour volume correlated significantly with IGF‐1R‐staining intensity in primary chordomas (<jats:italic>P </jats:italic>=<jats:italic> </jats:italic>0.042).</jats:p><jats:p><jats:bold>Conclusions: </jats:bold> IGF‐1R and IGF‐1 are expressed in the majority of chordomas. IGF‐1 expression is much stronger than IGF‐2 expression. Patients whose chordomas show a moderate to strong staining intensity in ≥50% of tumour cells for IGF‐1R (36%) might benefit most from IGF‐1R targeting, particularly if they suffer from large and surgically non‐resectable chordomas.</jats:p>